Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit medical products

The Executive Board, having considered the report of the fifth meeting of the Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit medical products\(^1\) and resolution WHA65.19 (2012),\(^2\) decided:

1. to endorse the definitions as set out in Appendix 3 to the Annex to document EB140/23;

2. to recommend that the Seventieth World Health Assembly:
   
   (a) endorse the definitions as set out in Appendix 3 to the Annex to document EB140/23;

   (b) request the Director-General to replace the term “substandard/spurious/falsely-labelled/falsified/counterfeit medical products” with “substandard and falsified medical products” as the term to be used in the name of the Member State mechanism and in all future documentation on the subject of medical products of this type.

(Eleventh meeting, 27 January 2017)

---

\(^1\) Document EB140/23.

\(^2\) See document WHA65/2012/REC/1, and in particular the footnote in the first paragraph of the Annex to the resolution.